NASDAQ:OCS Oculis Q3 2025 Earnings Results & Report $7.61 -0.03 (-0.43%) Closing price 03:59 PM EasternExtended Trading$7.63 +0.02 (+0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Oculis beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.40 versus the -$0.50 consensus estimate, while revenue of $305 thousand topped the $225 thousand estimate by $80.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call4:00 PM ET Oculis EPS ResultsActual EPS-$0.40Consensus EPS -$0.50Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersOculis Revenue ResultsActual Revenue$305 thousandExpected Revenue$225 thousandBeat/MissBeat by +$80.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) Oculis Q3 2025 Earnings FAQ Did Oculis beat earnings estimates for Q3 2025? Oculis (NASDAQ:OCS) reported earnings of -$0.40 per share for Q3 2025, beating the consensus estimate of -$0.50. The report was announced on Monday, November 10, 2025. What was Oculis' revenue for Q3 2025? Oculis reported revenue of $305 thousand for Q3 2025, against a consensus estimate of $225 thousand. Oculis Earnings HeadlinesOculis Gets FDA Clearance To Advance Privosegtor In Acute Multiple Sclerosis Relapses3 hours ago | rttnews.comOculis Expands Privosegtor Into Multiple Sclerosis Following IND ClearanceNovember 16 at 7:45 AM | rttnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)Oculis Announces FDA IND Clearance for Privosegtor in Acute MS RelapsesNovember 16 at 2:31 AM | quiverquant.comQOculis Gains FDA IND Clearance for Privosegtor in Acute MS RelapsesNovember 16 at 2:31 AM | quiverquant.comQOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesNovember 16 at 2:00 AM | globenewswire.comSee More Oculis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email. Email Address About OculisOculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.View Oculis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.